COVID-19 Infection in Patients With Hepatocellular Carcinoma

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma COVID-19 Carcinoma Carcinoma, Hepatocellular Coronaviridae Infections Coronavirus Infections Digestive System Diseases Digestive System Neoplasms Infections Liver Diseases Liver Neoplasms Lung Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens

Amiens, 80480, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with CHC and included in the French national prospective cohort CHIEF
Hospital and ambulatory patients
Infection confirmed by COVID-19 defined by a positive nasopharyngeal PCR or if PCR COVID-19 negative : CT showing COVID-19 compatible pneumonia
Suspected COVID-19 infection, not confirmed by COVID-19 PCR or chest CT, with no other known cause of acute pneumonia.

Exclusion criteria

Patient refusal
Influenza only, confirmed by a diagnostic test
Other proven causes of pneumonia and absence of COVID-19

Treatment and study plan

nasopharyngeal Covid 19 RT-PCR

Diagnostic Test

nasopharyngeal Covid 19 RT-PCR

Primary outcomes

Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Time frame: 6 months

Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Collaborators

CHU CRETEIL
CHU VILLEJUIF
Central Hospital, Nancy, France
Centre Hospitalier Général CORBEIL-ESSONNE
Centre Hospitalier Universitaire de Nice
Centre Hospitalier-Universitaire Bondy
Centre Hospitalier-Universitaire CLICHY
Hospices Civils de Lyon
Poitiers University Hospital
Rennes University Hospital
University Hospital, Bordeaux
University Hospital, Grenoble
University Hospital, Lille
University Hospital, Montpellier
University Hospital, Rouen
University Hospital, Toulouse

Registry information

Official study title

Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

Acronym: COVID19-CHIEF

Important dates

Study start: 2020
Primary completion: 2024
Study completion: 2026
First posted: Apr 29, 2020
Registry last updated: Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting